MBody AI Ltd CHEK Stock Analysis

About MBody AI Ltd

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan ®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. C-Scan is an investigational device and is not available for sale in the United States. Important Additional Information and Where to Find It In connection with the business combination, Nobul intends to file with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form F-4 containing a prospectus with respect to common shares of Nobul to be issued in the business combination, and Check-Cap intends to deliver a proxy statement to its shareholders in connection with the special meeting of its shareholders. Nobul also intends to file a prospectus concerning the business combination with the relevant Canadian securities commissions. Check-Cap and Nobul may also file other documents with the SEC and relevant Canadian securities commissions (as applicable) regarding the business combination. This press release is not a substitute for the prospectus or any other document which Nobul or Check-Cap may file with the SEC and Canadian securities commissions (as applicable). INVESTORS, NOBUL SECURITY HOLDERS AND CHECK-CAP SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE OR WILL BE FILED BY NOBUL OR CHECK-CAP WITH THE SEC AND RELEVANT CANADIAN SECURITIES COMMISSIONS (AS APPLICABLE), AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND RELATED MATTERS.